Cancers, Vol. 16, Pages 1515: First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA)
Cancers, Vol. 16, Pages 1515: First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA)
Cancers doi: 10.3390/cancers16081515
Authors:
Jean-Louis Legoux
Roger Faroux
Nicolas Barrière
Karine Le Malicot
David Tougeron
Véronique Lorgis
Véronique Guerin-Meyer
Vincent Bourgeois
David Malka
Thomas Aparicio
Matthieu Baconnier
Valérie Lebrun-Ly
Joëlle Egreteau
Faïza Khemissa Akouz
Magali Terme
Côme Lepage
Valérie Boige
Fluropyrimidine monotherapy is an option for some patients with inoperable metastatic colorectal cancer. Unlike bevacizumab, the addition of aflibercept, an antibody acting as an anti-angiogenic agent, has never been evaluated in this context. The aim of the study was to determine whether aflibercept could increase the efficacy of fluoropyrimidine monotherapy without increasing toxicity. This multicenter phase II non-comparative trial evaluated the addition of aflibercept to infusional 5-fluorouracil/folinic acid (LV5FU2 regimen) as first-line treatment in patients unfit to receive doublet cytotoxic chemotherapy. The primary endpoint was 6-month progression-free survival (PFS). The clinical hypotheses expected a PFS rate at 6 months of over 40% (60% expected). A total of 117 patients, with a median age of 81 years, were included: 59 in arm A (LV5FU2-aflibercept) and 58 in arm B (LV5FU2 alone). Six-month PFS was 54.7% in bo...
Source: Cancers - Category: Cancer & Oncology Authors: Jean-Louis Legoux Roger Faroux Nicolas Barri ère Karine Le Malicot David Tougeron V éronique Lorgis V éronique Guerin-Meyer Vincent Bourgeois David Malka Thomas Aparicio Matthieu Baconnier Val érie Lebrun-Ly Jo ëlle Egreteau Fa ïza Khemissa Akouz Ma Tags: Article Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Study | Toxicology | Vitamin B9